相关实验视频

Updated: Mar 12, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

解开Cuochuangling药丸在治疗中的机制:结合网络药理学,生物信息学和实验验证的综合方法

Xiaoying Shen^1,2, Donghu Liu^2,3, Zhengjin Zhu^1,2

¹Department of Dermatology, Shaanxi Provincial Hospital of Chinese Medicine, Xi'an, Shaanxi, People's Republic of China.

Clinical, cosmetic and investigational dermatology

|March 11, 2026

概括

黄药 (CCLP) 通过向IL-1β/TLR2/NF-κB通路,有效治疗粉红病. 这种草药配方可降低疹病例中的炎症和巨细胞透.

科学领域:

综合医学是一个整体的医学.
药理学药理学是指药理学的学科.
生物信息学是一种生物信息学.

背景情况:

红是一种慢性炎症性皮肤疾病,治疗选择有限.
(Cuochuangling) 药丸 (CCLP) 是一种传统的草药配方,在临床上用于治疗粉红.
对于CCLP的精确治疗机制仍然不完全理解.

研究的目的:

为了阐明CCLP对疹的治疗机制.
结合网络药理学,生物信息学和实验验证,进行全面的分析.
确定CCLP针对粉红病的行动中涉及的关键目标和途径.

主要方法:

网络药理学确定了CCLP的活性成分和目标.
生物信息学分析 (转录学,WGCNA,机器学习) 选了核心目标.
分子对接和动力学模拟评估了联体受体相互作用.
一个LL-37诱导的小鼠粉红病模型被用于体内验证.
组织病理学,ELISA和免疫组织化学评估了治疗效果.

主要成果:

介质蛋白-1β (IL-1β) 被确定为核心治疗标.
奎尔赛丁对IL-1β表现出强烈的结合亲和力,由分子动力学证实.
在体内,CCLP治疗显著降低了红血,严重程度和巨细胞透.
CCLP降低了关键的炎症标志物,包括IL-1β,IL-6,TNF-α,TLR2,KLK5和MMP9.

结论:

通过调节TLR2 / NF-κB信号通路,CCLP可以缓解类似疹的皮肤炎.
这项研究提供了关于CCLP在疹治疗中的疗效的机制性见解.
这种综合方法验证了CCLP在治疗粉红病中的治疗潜力.

关键词:

生物信息学是一种生物信息学.分子对接的分子对接.分子动力学模拟,分子动力学模拟网络药理学网络药理学罗萨西亚 (Rosacea) 是一种红色的疾病.传统的中国医药传统的中国医药.

更多相关视频

Rose Bengal-Mediated Photodynamic Therapy to Inhibit Candida albicans

Rose Bengal-Mediated Photodynamic Therapy to Inhibit Candida albicans

Published on: March 24, 2022

Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD

Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD

Published on: September 27, 2024

相关概念视频

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Cholinergic Antagonists: Pharmacokinetics

Cholinergic Antagonists: Pharmacokinetics

Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...